Varenicline - Pfizer
Alternative Names: Champix; Chantix; CP-526,555; CP-526555-18; Varenicline tartrateLatest Information Update: 05 Nov 2023
At a glance
- Originator Pfizer
- Class 3-ring heterocyclic compounds; Antivirals; Azabicyclo compounds; Benzazepines; Bridged-ring heterocyclic compounds; Eye disorder therapies; Pyrazines; Quinoxalines; Small molecules; Smoking cessation therapies
- Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Smoking withdrawal
- Discontinued Alzheimer's disease
Most Recent Events
- 29 Dec 2022 Varenicline is not yet available for Smoking withdrawal in Liechtenstein and Iceland
- 02 Feb 2022 Pfizer in collaboration with University of Oklahoma terminates phase II trial for Smoking withdrawal in the US (NCT03722966)
- 01 Sep 2021 Withdrawn for Smoking withdrawal in Indonesia, Brazil, Chile, Mexico, New Zealand, Singapore, China, Russia, South Africa, Hungary, Netherlands, Philippines, Israel, Hong Kong, Norway, Ireland, Italy, Sweden, Spain, Czech Republic, Australia, Germany, Argentina, India, Austria, Denmark, Japan, Ukraine, Switzerland, Portugal, Venezuela, United Kingdom, Turkey, France, Finland, Greece, Belgium, Poland, Malaysia, Canada (PO)